NTLA Q2 2025 Earnings — Intellia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

NTLAIntellia Therapeutics, Inc.

$2B

Q2 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+104.8% YoY

Gross Profit

$14M100.0% margin

Operating Income

-$110M-772.2% margin

Net Income

-$101M-710.8% margin

EPS (Diluted)

$-0.98

QoQ Revenue Growth

-14.3%

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$100M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$899M

Total Liabilities

$184M

Stockholders' Equity

$715M

Cash & Equivalents

$156M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$7M	+104.8%
Gross Profit	$14M	$4M	+226.9%
Operating Income	-$110M	-$139M	+20.9%
Net Income	-$101M	-$147M	+31.1%